S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Price, News & Analysis

$9.65
+0.38 (+4.10%)
(As of 03/28/2024 ET)
Today's Range
$9.20
$9.71
50-Day Range
$8.68
$17.36
52-Week Range
$3.81
$17.78
Volume
242,995 shs
Average Volume
266,833 shs
Market Capitalization
$567.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.80

IGM Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
84.5% Upside
$17.80 Price Target
Short Interest
Bearish
22.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
1.23mentions of IGM Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$3.17 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.23) to ($3.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

266th out of 938 stocks

Pharmaceutical Preparations Industry

124th out of 435 stocks

IGMS stock logo

About IGM Biosciences Stock (NASDAQ:IGMS)

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Stock Price History

IGMS Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
IGMS Apr 2024 22.500 call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
RBC Capital upgrades IGM Biosciences to outperform
IGM Biosciences Inc Ordinary Shares IGMS
BofA gets more bearish on IGM Biosciences, downgrades shares
IGM Biosciences downgraded to Neutral from Buy at H.C. Wainwright
What To Know About HC Wainwright & Co.'s Downgrade of IGM Biosciences
Antibody drugmaker IGM to cut 20% of jobs
See More Headlines
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
224
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$17.80
High Stock Price Target
$26.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+84.5%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-246,420,000.00
Net Margins
-11,568.83%
Pretax Margin
-11,537.00%

Debt

Sales & Book Value

Annual Sales
$2.13 million
Book Value
$3.46 per share

Miscellaneous

Free Float
25,331,000
Market Cap
$567.32 million
Optionable
Optionable
Beta
0.30

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 71)
    CEO, President & Director
    Comp: $977.66k
  • Dr. Bruce A. Keyt (Age 71)
    Chief Scientific Officer
    Comp: $692.95k
  • Dr. Chris H. Takimoto FACP (Age 65)
    M.D., Ph.D., Chief Medical Officer
    Comp: $684.95k
  • Mr. Misbah Tahir (Age 49)
    Chief Financial Officer
    Comp: $957.6k
  • Mr. TS Harigopal
    Senior Vice President of Group Operations
  • Mr. Steven Weber (Age 48)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Mr. Paul C. Graffagnino
    Vice President of Legal Affairs
  • Ms. Suzette Tauber (Age 60)
    Chief Human Resources Officer
  • Dr. Angus M. Sinclair Ph.D.
    Senior Vice President of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Business Officer
    Comp: $528.18k

IGMS Stock Analysis - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IGMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IGMS, but not buy additional shares or sell existing shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price target for 2024?

9 brokerages have issued 1-year target prices for IGM Biosciences' stock. Their IGMS share price targets range from $7.00 to $26.00. On average, they predict the company's share price to reach $17.80 in the next year. This suggests a possible upside of 84.5% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2024?

IGM Biosciences' stock was trading at $8.31 at the beginning of 2024. Since then, IGMS shares have increased by 16.1% and is now trading at $9.65.
View the best growth stocks for 2024 here
.

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,760,000 shares, an increase of 5.5% from the February 29th total of 4,510,000 shares. Based on an average trading volume of 291,100 shares, the days-to-cover ratio is presently 16.4 days. Approximately 22.9% of the shares of the stock are sold short.
View IGM Biosciences' Short Interest
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.03. The firm had revenue of $0.45 million for the quarter, compared to analysts' expectations of $0.80 million. IGM Biosciences had a negative net margin of 11,568.83% and a negative trailing twelve-month return on equity of 103.20%. The company's revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.33) earnings per share.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (5.58%), Price T Rowe Associates Inc. MD (5.58%), Goldman Sachs Group Inc. (1.78%), Goldman Sachs Group Inc. (1.78%), Vanguard Group Inc. (1.54%) and Vanguard Group Inc. (1.54%). Insiders that own company stock include Bros Advisors Lp Baker, Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Steven Weber.
View institutional ownership trends
.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IGMS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners